- Home
- DSS vs RDHL Comparison
DSS vs RDHL Comparison
Compare DSS & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSS
- RDHL
- Stock Information
- Founded
- DSS 1984
- RDHL 2009
- Country
- DSS United States
- RDHL Israel
- Employees
- DSS N/A
- RDHL N/A
- Industry
- DSS Containers/Packaging
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- DSS Consumer Discretionary
- RDHL Health Care
- Exchange
- DSS Nasdaq
- RDHL Nasdaq
- Market Cap
- DSS 7.3M
- RDHL 6.8M
- IPO Year
- DSS N/A
- RDHL N/A
- Fundamental
- Price
- DSS $0.95
- RDHL $5.23
- Analyst Decision
- DSS
- RDHL
- Analyst Count
- DSS 0
- RDHL 0
- Target Price
- DSS N/A
- RDHL N/A
- AVG Volume (30 Days)
- DSS 18.3K
- RDHL 10.4K
- Earning Date
- DSS 03-26-2025
- RDHL 04-07-2025
- Dividend Yield
- DSS N/A
- RDHL N/A
- EPS Growth
- DSS N/A
- RDHL N/A
- EPS
- DSS N/A
- RDHL N/A
- Revenue
- DSS $25,019,000.00
- RDHL $3,707,000.00
- Revenue This Year
- DSS N/A
- RDHL $224.90
- Revenue Next Year
- DSS N/A
- RDHL $82.69
- P/E Ratio
- DSS N/A
- RDHL N/A
- Revenue Growth
- DSS N/A
- RDHL N/A
- 52 Week Low
- DSS $0.77
- RDHL $5.20
- 52 Week High
- DSS $2.30
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- DSS 56.49
- RDHL 31.92
- Support Level
- DSS $0.81
- RDHL $5.52
- Resistance Level
- DSS $0.97
- RDHL $5.71
- Average True Range (ATR)
- DSS 0.07
- RDHL 0.27
- MACD
- DSS 0.01
- RDHL -0.04
- Stochastic Oscillator
- DSS 81.82
- RDHL 2.38
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.